Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BZE2204 in Relapsed/Refractory Multiple Myeloma
NCT06732232Phase 1Recruiting
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BZE2204 in multiple myeloma (MM), sponsored by Shanghai Cell Therapy Group. Primary endpoints: Dose-limiting toxicity and Maximum Tolerated Dose. Started Dec 2024; status: recruiting.
02
Drugs
BZE2204
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06732232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732232.